JP2017536398A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536398A5 JP2017536398A5 JP2017529604A JP2017529604A JP2017536398A5 JP 2017536398 A5 JP2017536398 A5 JP 2017536398A5 JP 2017529604 A JP2017529604 A JP 2017529604A JP 2017529604 A JP2017529604 A JP 2017529604A JP 2017536398 A5 JP2017536398 A5 JP 2017536398A5
- Authority
- JP
- Japan
- Prior art keywords
- solid dispersion
- arn
- hpmcas
- formulation
- weight ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007962 solid dispersion Substances 0.000 claims description 35
- HJBWBFZLDZWPHF-UHFFFAOYSA-N apalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S HJBWBFZLDZWPHF-UHFFFAOYSA-N 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 17
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 239000006185 dispersion Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 238000001125 extrusion Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000006104 solid solution Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 11
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 229960004103 abiraterone acetate Drugs 0.000 claims 1
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical group C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 claims 1
- 239000003098 androgen Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
- 229960004618 prednisone Drugs 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012088 reference solution Substances 0.000 description 1
- 238000010971 suitability test Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14196594.7 | 2014-12-05 | ||
| EP14196594 | 2014-12-05 | ||
| PCT/US2015/063661 WO2016090098A1 (en) | 2014-12-05 | 2015-12-03 | Anticancer compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020076516A Division JP7174006B2 (ja) | 2014-12-05 | 2020-04-23 | 抗癌性組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017536398A JP2017536398A (ja) | 2017-12-07 |
| JP2017536398A5 true JP2017536398A5 (OSRAM) | 2019-01-24 |
| JP6937692B2 JP6937692B2 (ja) | 2021-09-22 |
Family
ID=52006906
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017529604A Active JP6937692B2 (ja) | 2014-12-05 | 2015-12-03 | 抗癌性組成物 |
| JP2020076516A Active JP7174006B2 (ja) | 2014-12-05 | 2020-04-23 | 抗癌性組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020076516A Active JP7174006B2 (ja) | 2014-12-05 | 2020-04-23 | 抗癌性組成物 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US20170360754A1 (OSRAM) |
| EP (2) | EP3226841B1 (OSRAM) |
| JP (2) | JP6937692B2 (OSRAM) |
| KR (2) | KR20200141533A (OSRAM) |
| CN (2) | CN114886852A (OSRAM) |
| AR (1) | AR102926A1 (OSRAM) |
| AU (3) | AU2015358490B2 (OSRAM) |
| BR (1) | BR112017011788A2 (OSRAM) |
| CA (1) | CA2969656A1 (OSRAM) |
| CL (1) | CL2017001371A1 (OSRAM) |
| CO (1) | CO2017005572A2 (OSRAM) |
| CR (1) | CR20170216A (OSRAM) |
| EA (1) | EA201791222A1 (OSRAM) |
| ES (1) | ES2996833T3 (OSRAM) |
| HR (1) | HRP20241719T1 (OSRAM) |
| HU (1) | HUE069689T2 (OSRAM) |
| IL (2) | IL252323B (OSRAM) |
| MA (1) | MA41107B1 (OSRAM) |
| MD (1) | MD3226841T2 (OSRAM) |
| MX (2) | MX387933B (OSRAM) |
| NZ (1) | NZ770528A (OSRAM) |
| PH (1) | PH12017500964A1 (OSRAM) |
| PL (1) | PL3226841T3 (OSRAM) |
| RS (1) | RS66323B1 (OSRAM) |
| SG (1) | SG11201704267VA (OSRAM) |
| SM (1) | SMT202400518T1 (OSRAM) |
| TW (2) | TWI702966B (OSRAM) |
| UA (1) | UA120950C2 (OSRAM) |
| WO (1) | WO2016090098A1 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2836424T3 (es) | 2012-09-26 | 2021-06-25 | Aragon Pharmaceuticals Inc | Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración |
| RS66323B1 (sr) | 2014-12-05 | 2025-01-31 | Aragon Pharmaceuticals Inc | Sastavi protiv raka |
| MA41111B1 (fr) | 2014-12-05 | 2021-09-30 | Aragon Pharmaceuticals Inc | Compositions anticancéreuses |
| UA129105C2 (uk) | 2017-10-16 | 2025-01-15 | Арагон Фармасьютикалз, Інк. | Антиандрогени для лікування неметастатичного резистентного до кастрації раку передміхурової залози |
| WO2020144647A1 (en) | 2019-01-10 | 2020-07-16 | Aragon Pharmaceuticals, Inc. | Pharmaceutical composition comprising apalutamide dispersed in apple sauce |
| US20210115517A1 (en) | 2019-01-30 | 2021-04-22 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer based on molecular subtypes |
| JP2022523094A (ja) | 2019-01-30 | 2022-04-21 | アラゴン ファーマシューティカルズ，インコーポレイテッド | 転移性去勢感受性前立腺癌の治療のための抗アンドロゲン剤 |
| WO2020239478A1 (en) | 2019-05-28 | 2020-12-03 | Pharma Mar, S.A. | Trabectedin for treating sarcomas based on genomic markers |
| EP3811932A1 (en) | 2019-10-22 | 2021-04-28 | Zentiva K.S. | Dosage form of apalutamide |
| CA3160121A1 (en) | 2019-11-04 | 2021-05-14 | Aragon Pharmaceuticals, Inc. | Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment |
| WO2021245285A1 (en) | 2020-06-05 | 2021-12-09 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer based on molecular subtypes |
| TW202228794A (zh) | 2020-09-04 | 2022-08-01 | 美商艾瑞岡醫藥公司 | 用於治療前列腺癌之方法 |
| WO2022195407A1 (en) | 2021-03-19 | 2022-09-22 | Aragon Pharmaceuticals, Inc. | Methods for treating prostate cancer |
| WO2023122842A1 (es) * | 2021-12-31 | 2023-07-06 | Gador Limitada | Proceso para la preparación de apalutamida, intermediarios de sintesis y la dispersion solida amorfa que la contiene |
| WO2023152611A1 (en) | 2022-02-11 | 2023-08-17 | Aragon Pharmaceuticals, Inc. | Apalutamide and relugolix for the treatment of prostate cancer |
| WO2023209555A1 (en) | 2022-04-26 | 2023-11-02 | Aragon Pharmaceuticals, Inc. | Approved drug products and methods for treating prostate cancer |
| CN116183787A (zh) * | 2022-12-26 | 2023-05-30 | 郑州德迈药业有限公司 | 醋酸羟丙甲纤维素琥珀酸酯在阿帕他胺溶出检测中的应用以及检测方法 |
| AU2024236119A1 (en) | 2023-03-16 | 2025-09-25 | Bayer Consumer Care Ag | Androgen receptor antagonists for the treatment of patients with biochemical recurrence of hormone sensitive prostate cancer |
| WO2025153768A1 (en) * | 2024-01-18 | 2025-07-24 | Nanoform Finland Oyj | Composition comprising crystalline nanosized apalutamide |
| WO2025174375A1 (en) * | 2024-02-15 | 2025-08-21 | Aragon Pharmaceuticals, Inc. | Anticancer compositions |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2265624B (en) | 1992-03-31 | 1995-04-19 | British Tech Group | 17-substituted steroids useful in cancer treatment |
| DE69837903T2 (de) | 1997-08-11 | 2008-02-14 | Pfizer Products Inc., Groton | Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit |
| WO2001060410A1 (en) | 2000-02-21 | 2001-08-23 | Takeda Chemical Industries, Ltd. | Sustained release preparations of physiologically active compound hardly soluble in water and production process and use of the same |
| JP3548566B2 (ja) | 2001-02-27 | 2004-07-28 | アストラゼネカ アクチボラグ | 医薬製剤 |
| WO2002080902A1 (en) | 2001-04-02 | 2002-10-17 | Astrazeneca Ab | Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp |
| ATE480226T1 (de) * | 2001-06-22 | 2010-09-15 | Bend Res Inc | Pharmazeutische zusammensetzung enthaltend schwer lösliche und säureempfindliche arzneistoffe und neutralisierte anionische polymere |
| SE0103424D0 (sv) * | 2001-10-15 | 2001-10-15 | Astrazeneca Ab | Pharmaceutical formulation |
| BR0307515A (pt) | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão |
| WO2003077827A1 (en) | 2002-03-19 | 2003-09-25 | Nippon Shinyaku Co., Ltd. | Process for producing drug solid dispersion |
| EP1694302A1 (en) | 2003-12-15 | 2006-08-30 | Council of Scientific and Industrial Research | TASTE MASKED PHARMACEUTICAL COMPOSITIONS COMPRISING BITTER DRUG AND pH SENSITIVE POLYMER |
| GB0502790D0 (en) | 2005-02-10 | 2005-03-16 | Univ London Pharmacy | Solid dispersion of hydrophobic bioactive |
| KR101332889B1 (ko) | 2005-05-13 | 2013-11-26 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 디아릴히단토인 화합물 |
| EP4385574A3 (en) * | 2006-03-27 | 2024-10-02 | The Regents of the University of California | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases |
| AU2010232670B2 (en) | 2009-04-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof |
| KR101819199B1 (ko) | 2010-02-16 | 2018-01-16 | 아라곤 파마슈티컬스, 인코포레이티드 | 안드로겐 수용체 조절제 및 이의 용도 |
| CN102525876B (zh) | 2010-12-15 | 2014-03-12 | 西安力邦医药科技有限责任公司 | 阿司匹林固体分散体、其制备方法、药物组合物和用途 |
| EP2721003B1 (en) | 2011-06-15 | 2018-01-03 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | Nuclear receptor modulators and their use for the treatment and prevention of cancer |
| US20150037407A1 (en) | 2012-03-21 | 2015-02-05 | Emphascience, Inc. | Method to improve the safety of handling of high potency drugs in solid dosage forms without changing their efficacy |
| WO2013152342A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Anti-cancer mtor inhibitor and anti-androgen combination |
| CN113135892A (zh) | 2012-06-07 | 2021-07-20 | 阿拉贡药品公司 | 雄激素受体调节剂的晶形 |
| US10668156B2 (en) | 2012-06-22 | 2020-06-02 | Basf Se | Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers |
| JP6215945B2 (ja) * | 2012-08-24 | 2017-10-18 | ダウ グローバル テクノロジーズ エルエルシー | 新規ヒドロキシアルキルメチルセルロースアセテートサクシネート |
| US9977033B2 (en) | 2012-09-11 | 2018-05-22 | The Board Of Regents Of The University Of Texas System | Methods for assessing cancer recurrence |
| EA033374B9 (ru) | 2012-09-11 | 2019-12-18 | Медивейшн Простейт Терапьютикс Ллк | Твердые фармацевтические композиции, содержащие энзалутамид, и способ лечения |
| ES2836424T3 (es) * | 2012-09-26 | 2021-06-25 | Aragon Pharmaceuticals Inc | Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración |
| JOP20200097A1 (ar) | 2013-01-15 | 2017-06-16 | Aragon Pharmaceuticals Inc | معدل مستقبل أندروجين واستخداماته |
| AU2014210103B2 (en) | 2013-01-22 | 2018-09-06 | F. Hoffmann-La Roche Ag | Pharmaceutical composition with improved bioavailability |
| TWI686212B (zh) | 2013-03-15 | 2020-03-01 | 阿聯商太陽法瑪全球有限公司 | 醋酸阿比特龍配方 |
| WO2014167428A2 (en) | 2013-04-10 | 2014-10-16 | Shilpa Medicare Limited | Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide |
| SG11201600525XA (en) * | 2013-08-12 | 2016-02-26 | Tokai Pharmaceuticals Inc | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
| US9566280B2 (en) | 2014-01-28 | 2017-02-14 | Massachusetts Institute Of Technology | Combination therapies and methods of use thereof for treating cancer |
| CN112402360A (zh) | 2014-02-05 | 2021-02-26 | 斯洛文尼亚莱柯制药股份有限公司 | 雄激素受体拮抗剂的固体药物组合物 |
| TWI718102B (zh) | 2014-08-08 | 2021-02-11 | 日商中外製藥股份有限公司 | ４環性化合物的非晶質體 |
| RS66323B1 (sr) | 2014-12-05 | 2025-01-31 | Aragon Pharmaceuticals Inc | Sastavi protiv raka |
| CN106999430A (zh) | 2014-12-05 | 2017-08-01 | 阿拉贡药品公司 | 抗癌组合物 |
| MA41111B1 (fr) | 2014-12-05 | 2021-09-30 | Aragon Pharmaceuticals Inc | Compositions anticancéreuses |
| SG11201809680QA (en) | 2016-06-03 | 2018-11-29 | Aragon Pharmaceuticals Inc | Anticancer compositions |
| WO2019242439A1 (zh) | 2018-06-20 | 2019-12-26 | 苏州科睿思制药有限公司 | Arn-509的晶型及其制备方法和用途 |
| EP3811932A1 (en) | 2019-10-22 | 2021-04-28 | Zentiva K.S. | Dosage form of apalutamide |
-
2015
- 2015-12-03 RS RS20241412A patent/RS66323B1/sr unknown
- 2015-12-03 HR HRP20241719TT patent/HRP20241719T1/hr unknown
- 2015-12-03 JP JP2017529604A patent/JP6937692B2/ja active Active
- 2015-12-03 KR KR1020207035390A patent/KR20200141533A/ko not_active Ceased
- 2015-12-03 WO PCT/US2015/063661 patent/WO2016090098A1/en not_active Ceased
- 2015-12-03 CN CN202210133724.8A patent/CN114886852A/zh active Pending
- 2015-12-03 US US15/533,188 patent/US20170360754A1/en not_active Abandoned
- 2015-12-03 AU AU2015358490A patent/AU2015358490B2/en active Active
- 2015-12-03 CN CN201580066233.4A patent/CN106999431B/zh active Active
- 2015-12-03 MA MA41107A patent/MA41107B1/fr unknown
- 2015-12-03 NZ NZ770528A patent/NZ770528A/en unknown
- 2015-12-03 ES ES15817641T patent/ES2996833T3/es active Active
- 2015-12-03 SM SM20240518T patent/SMT202400518T1/it unknown
- 2015-12-03 EA EA201791222A patent/EA201791222A1/ru unknown
- 2015-12-03 UA UAA201707020A patent/UA120950C2/uk unknown
- 2015-12-03 EP EP15817641.2A patent/EP3226841B1/en active Active
- 2015-12-03 CR CR20170216A patent/CR20170216A/es unknown
- 2015-12-03 KR KR1020177018239A patent/KR102348320B1/ko active Active
- 2015-12-03 MX MX2017007203A patent/MX387933B/es unknown
- 2015-12-03 CA CA2969656A patent/CA2969656A1/en active Pending
- 2015-12-03 PL PL15817641.2T patent/PL3226841T3/pl unknown
- 2015-12-03 BR BR112017011788A patent/BR112017011788A2/pt not_active Application Discontinuation
- 2015-12-03 EP EP24202355.4A patent/EP4494636A3/en active Pending
- 2015-12-03 MD MDE20170152T patent/MD3226841T2/ro unknown
- 2015-12-03 HU HUE15817641A patent/HUE069689T2/hu unknown
- 2015-12-03 SG SG11201704267VA patent/SG11201704267VA/en unknown
- 2015-12-04 TW TW104140822A patent/TWI702966B/zh active
- 2015-12-04 AR ARP150103982A patent/AR102926A1/es not_active Application Discontinuation
- 2015-12-04 TW TW109112959A patent/TWI754258B/zh active
-
2017
- 2017-05-16 IL IL252323A patent/IL252323B/en active IP Right Grant
- 2017-05-25 PH PH12017500964A patent/PH12017500964A1/en unknown
- 2017-05-29 CL CL2017001371A patent/CL2017001371A1/es unknown
- 2017-06-05 MX MX2021013965A patent/MX2021013965A/es unknown
- 2017-06-05 CO CONC2017/0005572A patent/CO2017005572A2/es unknown
-
2020
- 2020-04-23 JP JP2020076516A patent/JP7174006B2/ja active Active
- 2020-12-29 IL IL279833A patent/IL279833B/en unknown
-
2021
- 2021-03-30 AU AU2021201979A patent/AU2021201979B2/en active Active
-
2023
- 2023-03-29 US US18/192,244 patent/US20230233529A1/en not_active Abandoned
- 2023-05-02 AU AU2023202710A patent/AU2023202710A1/en not_active Abandoned
-
2024
- 2024-05-10 US US18/660,698 patent/US12303493B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017536398A5 (OSRAM) | ||
| JP2017536401A5 (OSRAM) | ||
| Li et al. | Quinolizidine alkaloids derivatives from Sophora alopecuroides Linn: Bioactivities, structure-activity relationships and preliminary molecular mechanisms | |
| HRP20211140T1 (hr) | Pripravci protiv raka | |
| HRP20241719T1 (hr) | Antitumorske smjese | |
| JP2019517497A5 (OSRAM) | ||
| HRP20201902T1 (hr) | Pripravci protiv raka | |
| Shalini et al. | Have molecular hybrids delivered effective anti-cancer treatments and what should future drug discovery focus on? | |
| CN105611918B (zh) | 含有他达拉非的口腔崩解型膜制剂及其制备方法 | |
| JP2017536407A5 (OSRAM) | ||
| FI2346495T4 (fi) | Farmaseuttinen formulaatio 514 | |
| JP2012236837A5 (OSRAM) | ||
| WO2024189607A1 (en) | Methods and bioavailable highly permeable compounds for diseases treatment | |
| JP2018504443A5 (OSRAM) | ||
| PH12015502134A1 (en) | Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration | |
| WO2012079092A3 (en) | Testosterone undecanoate compositions | |
| JP2012025755A5 (OSRAM) | ||
| JP2011225600A5 (OSRAM) | ||
| JP2016539953A5 (OSRAM) | ||
| JP2014516080A5 (OSRAM) | ||
| HRP20191366T1 (hr) | Injekcijski pripravak | |
| WO2015034678A3 (en) | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis | |
| WO2014118808A3 (en) | Ticagrelor solid dispersion | |
| BR102013020508B1 (pt) | Forma de dosagem que compreende um inibidor de esteroide 5-alfa-redutase e um bloqueador alfa, processo para a preparaçãode uma forma de dosagem e uso da forma de dosagem | |
| JP2015514739A5 (OSRAM) |